Super-enhancers (SEs), which are composed of large clusters of enhancers densely loaded with the Mediator complex, transcription factors and chromatin regulators, drive high expression of genes implicated in cell identity and disease, such as lineagecontrolling transcription factors and oncogenes 1, 2 . BRD4 and CDK7 are positive regulators of SE-mediated transcription [3] [4] [5] . By contrast, negative regulators of SE-associated genes have not been well described. Here we show that the Mediator-associated kinases cyclin-dependent kinase 8 (CDK8) and CDK19 restrain increased activation of key SE-associated genes in acute myeloid leukaemia (AML) cells. We report that the natural product cortistatin A (CA) selectively inhibits Mediator kinases, has anti-leukaemic activity in vitro and in vivo, and disproportionately induces upregulation of SE-associated genes in CA-sensitive AML cell lines but not in CAinsensitive cell lines. In AML cells, CA upregulated SE-associated genes with tumour suppressor and lineage-controlling functions, including the transcription factors CEBPA, IRF8, IRF1 and ETV6 (refs 6-8) . The BRD4 inhibitor I-BET151 downregulated these SEassociated genes, yet also has anti-leukaemic activity. Individually increasing or decreasing the expression of these transcription factors suppressed AML cell growth, providing evidence that leukaemia cells are sensitive to the dosage of SE-associated genes. Our results demonstrate that Mediator kinases can negatively regulate SE-associated gene expression in specific cell types, and can be pharmacologically targeted as a therapeutic approach to AML.
CDK8 associates with CCNC (cyclin C), MED12 and MED13 to form a CDK8 module that can reversibly associate with the 26-subunit Mediator complex 9 . Because SEs are disproportionately loaded with Mediator 2 , we examined whether CDK8, as a Mediator-associated kinase, might regulate SE function. Using chromatin immunoprecipitation followed by sequencing (ChIP-seq), we mapped the genomewide occupancy of CDK8, along with known SE-associated factors and histone modifications, in the AML cell line MOLM-14. Semisupervised hierarchical clustering revealed that CDK8 most closely associated with MED1, followed by BRD4 and histone 3 Lys27 acetylation (H3K27ac), at putative enhancer elements marked with H3K4me1 (red bar, Fig. 1a and Extended Data Fig. 1a-c) . A fraction of these regions was particularly large and loaded with CDK8, MED1 and BRD4, suggesting that they may represent SEs. Consistent with this notion, most of the CDK8, MED1, BRD4 and H3K27ac ChIP-seq signal was disproportionately located on a small number of SEs identified by each factor separately (Extended Data Fig. 1d-f ). These SEs significantly overlapped (Fig. 1b, c and Supplementary Table 1 ). Genes associated with these SEs were enriched with Gene Ontology (GO) terms pertinent to haematopoiesis, cellular differentiation and transcription, supporting the notion that SEs regulate cellular identity (Supplementary Table 1 ).
To determine whether pharmacological inhibition of Mediator kinases regulates SE function and inhibits AML proliferation, in analogy to BRD4, we characterized CA ( Fig. 2a ) as an inhibitor of CDK8 and its paralogue CDK19 (77% identical overall and 94% in the catalytic domain). CA was reported to bind CDK8 and CDK19, as well as ROCK1 and ROCK2, as individual proteins in vitro 10 . We synthesized CA 11, 12 and determined that it potently inhibited the kinase activity of the CDK8 module in vitro (half-maximum inhibitory concentration (IC 50 ) 5 12 nM; Fig. 2b and Extended Data Fig. 2a ). By contrast, CA did not inhibit other transcriptional cyclin-dependent kinases CDK7 (TFIIH), CDK9 (P-TEFb), CDK12 or CDK13 in vitro, nor did it bind CDK9, CDK12, CDK13, ROCK1 or ROCK2 up to 2,500 nM in a, Clustering of total ChIP-seq signal of CDK8, MED1, BRD4, H3K27ac, RNA pol II and H3K4me1 on CDK8-positive regions. Each respective cluster is ordered by CDK8 signal. The red bar indicates the cluster most highly enriched for the factors listed above. b, Overlap between SEs independently identified by ChIP-seq signal for CDK8, MED1 and BRD4 based on the collapsed superset of regions identified by any one factor. c, ChIP-seq binding profiles at the CEBPA locus.
MOLM-14 cell lysate ( Fig. 2b and Extended Data Fig. 2b, c) . In cells, CA dose-dependently inhibited the phosphorylation of known CDK8 substrates STAT1-S727 (ref. 13 ; IC 50 , 10 nM), Smad2-T220 and Smad3-T179 (ref. 14; IC 50 , 100 nM) (Extended Data Fig. 2d ). No kinase substrates have been reported for CDK19. We more broadly evaluated CA selectivity in cell lysate (using KiNativ, see Methods) 15 and in vitro, which collectively tested 387 kinases. At 100-times its CDK8 IC 50 value, CA was fully selective in MOLM-14 cell lysate for CDK8 and CDK19, and in vitro only inhibited the CDK8-CCNC complex and GSG2, the latter of which we disqualified as a cellular target of CA ( Fig. 2c , Extended Data Fig. 2c , e-h, Supplementary Table 2 and Supplementary Information). CA also exhibited high affinity binding (equilibrium dissociation constant (K d ) 5 195 6 15.8 pM (mean 6 s.e.m.)), slow binding kinetics (dissociation rate constant (k off ) 5 6.35 3 10 25 6 8.15 3 10 26 s 21 , association rate constant (k on ) 5 3.26 3 10 5 6 1.54 3 10 4 s 21 M 21 ) and a long residence time (262 6 34 min) in its interaction with CDK8-CCNC complex in vitro.
To understand how CA inhibits CDK8, we obtained a highresolution (2.4 Å ) crystal structure of a CA-CDK8-CCNC ternary complex ( Fig. 2d and Extended Data Fig. 3 ). CA exhibits exquisite shape complementarity with the ATP-binding pocket of CDK8. In particular, the isoquinoline of CA forms N-H and CH-O hydrogen bonds with Ala100 (ref. 16) , the C5-C8 ethano bridge and the C13methyl group of CA occupy deep hydrophobic crevices in the ATPbinding site, and the protonated C3 N,N-dimethylamine of CA engages in an apparent cation-p interaction with Trp105 (ref. 17) .
We investigated the antiproliferative activity of CA and observed that it inhibited the proliferation (half-maximum growth inhibition concentration (GI 50 ) , 10 nM) of several myeloid, mixed-lineage and megakaryoblastic leukaemia cell lines containing diverse oncogenic contributors, including mixed lineage leukaemia (MLL) fusions (MOLM-14, MV4;11 and RS4;11 cells), RUNX1-RUNX1T1 (SKNO-1), JAK2(V617F) (SET-2 and UKE-1) and BCR-ABL (MEG-01) ( Fig. 2e , Extended Data Table 1 and Extended Data Fig. 4a ). CA inhibited CDK8 kinase activity in both sensitive and insensitive cell lines with similar potency, and did not alter CDK8 or CDK19 protein levels (Extended Data Fig. 4b, c ). Although SET-2 and HEL cell lines contain the JAK2(V617F) mutation, and MEG-01 and K562 contain the BCR-ABL translocation, megakaryoblastic cell lines SET-2 and MEG-01 cells were sensitive to CA whereas erythroleukaemia-derived cell lines HEL and K562 were not, suggesting that cell lineage may be a contributing determinant for CA sensitivity 18 . The phenotypic effects of CA were cell-line-dependent. CA treatment increased megakaryocyte markers CD41 and CD61 on SET-2 cells, whereas CA treatment of MOLM-14, MV4;11 and SKNO-1 cells increased cleaved PARP levels, annexin V staining and the sub-G1 cell population, consistent with apoptosis (Extended Data Fig. 4d-f ).
We confirmed that Mediator kinases mediate the antiproliferative activity of CA by identifying a point mutant of CDK8 and CDK19, W105M, that maintained catalytic activity but specifically conferred resistance to CA (Fig. 2f , g and Extended Data Fig. 5a -f). Notably, CDK8 and CDK19 are the only mammalian cyclin-dependent kinases with Trp (or any aromatic amino acid) at residue 105 (Extended Data Fig. 5g ), underscoring the importance of the putative cation-p interaction.
Next, we used CA to investigate whether Mediator kinase activity regulates SE-associated gene expression in AML cells. Global gene expression profiling in MOLM-14 cells treated with CA revealed that genes upregulated by CA at 3 h were highly enriched for association with SEs by gene set enrichment analysis (GSEA) 19 (Fig. 3a, b , Extended Data Fig. 6a and Supplementary Table 3 ). These SEassociated gene sets ranked among the most significantly enriched compared to all other signatures tested ( Fig. 3c ). Genes upregulated ($1.2-fold) by CA were disproportionately associated with SEs in MOLM-14 cells (49 out of 251, 20%) compared to regular enhancers (173 out of 5,034, 3%) (Extended Data Fig. 6b , Fisher's exact test, P , 2.2 3 10 216 ). By contrast, of 102 genes downregulated ($1.2-fold) by CA, only three were identified as SE-associated (3 out of 102, 3%). Furthermore, the association between CA-upregulated genes ($1.2-fold) and SE-associated genes correlated with CDK8 occupancy (Fisher's exact test, P 5 2.5 3 10 28 ), consistent with the notion that SEs are direct targets of CA treatment in MOLM-14 cells (Extended Data Fig. 6b ). kinases. a, CA structure with N,N-dimethylamine in red, C5-C8 ethano bridge in magenta, C13-methyl in green and isoquinoline in blue. b, Phosphorylation of the RNA pol II CTD (mean 6 s.e.m., n 5 3 biological replicates, one of two experiments shown, autorad in Supplementary Fig. 1 ). c, Kinome profiling in MOLM-14 lysate (mean, n 5 2 biological replicates, experiment performed once, values , 35% indicate no change). d, CA-binding pocket of CDK8 from CA-CDK8-CCNC crystal structure (semi-transparent surface; CA in gold, CDK8 in grey) with contact residues and CA in stick representation. Dotted red lines indicate hydrogen bonds. e, Effect of CA on growth of indicated cell lines (mean 6 s.e.m., n 5 3 biological replicates, one of two experiments shown). f, Sensitivity of MOLM-14 cells to CA after expression of indicated kinases (mean 6 s.e.m., n 5 3 biological replicates, one of two experiments shown). g, Immunoblot showing IFN-c-stimulated STAT1-S727 phosphorylation in MOLM-14 cells expressing indicated kinases and treated with CA (one of two experiments shown, full scan in Supplementary Fig. 1 ).
Because SE-associated genes are more highly expressed compared to regular enhancer-associated genes, we determined whether genes upregulated by CA had elongating RNA polymerase (pol) II and reduced travelling ratios 20 (ratio of RNA pol II ChIP-seq reads in the proximal promoter versus the gene body). Indeed, CA-upregulated genes exhibited a reduced baseline travelling ratio (2.40-fold, P , 2.2 3 10 216 , red versus black curve, Fig. 3d and Extended Data Fig. 6c, d ), consistent with CA upregulating active genes, including those associated with SEs. CA treatment further reduced the travelling ratio of these 'CA-upregulated' genes to a level similar to all SE-associated genes (yellow curve), in agreement with their increased expression after CA treatment (1.48-fold, P 5 7.6 3 10 24 , blue versus red curve, Fig. 3d ). Genes downregulated by CA experienced insignificant changes in the travelling ratio (Extended Data Fig. 6e ). Global effects of CA on the RNA pol II travelling ratio, RNA pol II carboxy-terminal domain (CTD) phosphorylation, messenger RNA and total RNA levels were modest or negligible (Extended Data Fig. 6f -h).
We then examined whether the upregulation of SE-associated genes might contribute to the antiproliferative activity of CA. SE-associated genes upregulated by CA were enriched in lineage-controlling master transcription factors identified in related CD14 1 monocytes 1 , including tumour suppressors IRF1, IRF8, CEBPA and ETV6 ( Fig. 3e and Extended Data Fig. 7a -c). Increased expression of these genes individually, as well as SE-associated genes FOSL2 and CDKN1B, inhibited the proliferation of MOLM-14 cells ( Fig. 3f and Extended Data Fig. 7d, e ). ChIP-seq data revealed CDK8 occupancy at the nearby SE of each gene (CEBPA, Fig. 1c ; and ETV6 and FOSL2, Extended Data Fig. 7f ). Furthermore, expression of CA-resistant CDK8(W105M) prevented upregulation of SEassociated genes by CA (Extended Data Fig. 7g ). Therefore, upregulation of SE-associated genes, through Mediator kinase inhibition, could contribute to the antiproliferative activity of CA.
Growth of several AML cell lines was sensitive to CA and the BRD4 inhibitor I-BET151 (Extended Data Table 1 ). The opposing effects of these inhibitors on SE-associated gene expression ( Fig. 3b , e (red ticks are SE-associated genes) and Extended Data Fig. 7c ), however, suggest that AML cells might depend on a precise 'dosage' of SE-associated gene expression. Indeed, MOLM-14 cell growth was inhibited by either reduced or increased expression of the same SE-associated genes, many of which were upregulated by CA and downregulated by I-BET151 (Fig. 3e , f and Extended Data Fig. 7c -e, h). Despite having opposing effects on SE-associated genes, CA and I-BET151 co-treatment did not normalize transcription of these genes. Instead, I-BET151-induced transcriptional effects dominated, suggesting a dependence on BRD4 for CAinduced transcription ( Fig. 3e and Extended Data Fig. 7c ). Consistent with this, I-BET151 caused reduced occupancy of BRD4 and CDK8 on enhancer regions, and CA and I-BET151 co-treatment inhibited MOLM-14 cell growth (Extended Data Fig. 7i , j).
We extended our gene expression, ChIP-seq and SE analyses to additional cell lines that were sensitive (SET-2 and MV4;11) and insensitive (HCT116 and K562) to CA, and found that only the sensitive cell lines showed statistically significant enrichment of SEassociated genes among those upregulated by CA ( Fig. 3g ). These results support upregulation of SE-associated genes as contributing to the antiproliferative effects of CA. However, we cannot exclude the contribution of other factors.
Finally, we assessed the in vivo antileukaemic activity of CA. We first determined that CA had acceptable pharmacokinetic properties in mice for once-daily intraperitoneal dosing (Extended Data Fig. 8a ) and then measured its efficacy in a disseminated human AML model 21 .
CA afforded a dose-dependent reduction in disease progression (P , 0.0001), spleen weight, leukaemia cell burden, and survival (29.5-day median extension in survival, P , 0.0001; Fig. 4a , b and Extended Data Fig. 8b-e ). Efficacious dosing was well-tolerated, with no loss in body weight or deleterious effects in peripheral blood of leukaemia-bearing or healthy, immunocompetent (CD-1) mice (Extended Data Fig. 8f , g, j-l). In a second AML model using SET-2 cells, CA afforded a 71% tumour volume reduction, also with no loss in body weight ( Fig. 4c and Extended Data Fig. 8h ). We confirmed that Δ mRNA copies per cell
-64
Sensitive, GI 50 < 10 nM Insensitive, GI 50 > 1,000 nM siRNA knockdown Inducible expression CA inhibited CDK8 in vivo by observing a dose-dependent reduction in STAT1-S727 phosphorylation in natural killer cells, which have CDK8-dependent constitutively phosphorylated STAT1-S727 ( Fig. 4d and Extended Data Fig. 8i ) 22 .
Although SE-associated genes are expressed at high levels, our results with CA show that a subset is restrained from even higher expression by Mediator kinase activity. The specificity, potency, favourable pharmacokinetics and long residence time of CA make it a useful in vitro and in vivo probe of Mediator kinases and a promising lead for development of therapeutics.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Author Information The atomic coordinates of CDK8-CCNC in complex with cortistatin A have been deposited in the Protein Data Bank (PDB) with accession number 4CRL. MIAME-compliant microarray data as well as aligned and raw ChIP-seq data were deposited to the Gene Expression Omnibus (GEO) with accession GSE65161. Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to M.D.S. (shair@chemistry.harvard.edu). a, Bioluminescent images of mice bearing MV4;11 leukaemia cells. Mouse with median bioluminescence shown, treatment as in b. Colour scale 1.00 3 10 6 to 1.00 3 10 8 . b, Mean 6 s.e.m., n 5 11 mice; P , 0.0001 for both doses on day 33 versus vehicle, two-way analysis of variance (ANOVA). IP, intraperitoneal. c, Mice containing SET-2 AML xenograft tumours and treated as indicated. Mean 6 s.e.m., n 5 10 mice; 71% tumour growth inhibition on day 33, P , 0.0001, two-tailed t-test. d, Densitometric analysis of STAT1-pS727 in natural killer cells isolated from the spleen of C57BL/6 mice treated with CA or vehicle (n 5 3 mice), STAT1-pS727 normalized to actin, P 5 0.011 for 0.625 mg kg 21 , one-way ANOVA, experiment performed once.
METHODS
Cell culture. All media was supplemented with 100 U ml 21 penicillin and 100 mg ml 21 streptomycin. Cell line media: MV4;11, RS4;11, K562, HEL, MOLM-14 and MEG-01 in RPMI-1640, 10% FBS; SET-2 in RPMI-1640, 20% FBS; UKE-1 in RPMI-1640, 10% FBS, 10% horse serum and 1 mM hydrocortisone; SKNO-1 and TF-1 in RPMI-1640, 10% FBS, plus 10 and 2 ng ml 21 . The assay included 2.5% DMSO, which did not inhibit kinase activity. 12% SDS-PAGE gels were subsequently silver-stained, exposed for 18 h on a Phosphor Screen and imaged (Typhoon 9400, GE Life Sciences). For pol II CTD, 400 ng of GST-CTD (mouse sequence) was incubated with ,40 ng recombinant CDK8 module, 25 ng TFIIH, or 40 ng P-TEFb at 30 uC for 60 min in kinase buffer. Kinase amounts were chosen to give similar total pol II CTD signal. 9% SDS-PAGE gels were silver stained and exposed as above. In vitro Flag-CDK8 kinase assays used ,40 ng kinase and 500 ng GST-CTD. CDK12(714-1063)-CCNK(1-267) and CDK13(694-1039)-CCNK(1-267) were expressed in insect cells and used at ,500 nM per reaction. These regions of CDK12/13 encompass the kinase domains (including the C-terminal extension helix) and the cyclin boxes, and are fully phosphorylated in the T-loop. For STAT1 or Smad2/3, cells were treated with compound for 1 h followed by IFN-c or TGF-b1 for 1 h, then washed twice with cold PBS, and lysed (RIPA buffer with inhibitors R0278, P8340, P0044 and P5762; Sigma-Aldrich 
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transferred in duplicate for CellTiter-Glo measurement. On days 3 and 7, an equal volume for all wells was split-back with fresh media and compound, such that the resulting cell density for the vehicle well matched the initial seeding density. For days 7 and 10, estimated cell number represents the split-adjusted theoretical cell number. HCT116 were plated (96-well) in triplicate at 250 cells per well. Cells were incubated in the presence of vehicle, 1 mM paclitaxel, or compound. On day 7, CellTiter-Blue (Promega) response was measured and values were normalized to vehicle (100% growth) and paclitaxel (0% growth). For growth assays with inhibitors, n 5 3 for each concentration with two independent experiments, averaged for Extended Data Table 1 , and one experiment shown for graphs of percentage growth versus concentration and time, Fig. 2e and Extended Data Fig. 4a . Microarrays were processed with Bioconductor packages affyQCReport 35 for quality control and affy for background correction, summarization, and normalization using rma 36 . Probe sets present in at least 1 sample (based on affy mas5call) and for which the interquartile range was .log 2 (1.2) were retained for further analysis. The limma Bioconductor package 37 was used for differential expression analysis of CA-treated versus DMSO control samples (Benjamini-Hochberg 38 adjusted P , 0.05). SET-2 and HCT116 gene expression was measured by RNA-seq. SET-2 RNA-seq libraries were prepared and processed using the Ion Torrent workflow. Reads were aligned in two passes, first with rnaStar 39 49 . Retained regions were assigned to one of the following categories: (1) promoter 5 transcription start site (TSS) 2 500 bp to TSS 1 200 bp, (2) body 5 TSS 1 201 bp to TES, (3) proximal enhancer 5 TSS 2 5 kb to TSS 2 501 bp, and (4) 39 untranslated region (UTR) 5 TES 1 1 bp to TES 1 5 kb. All other regions were termed 'desert' hits. Any gene satisfying the overlap criteria was included in the corresponding category. Travelling ratios were calculated essentially as described 50 . In brief, mapped read coordinates were first extended 39 to 200 bases to capture the full fragment coverage. The RefSeq coordinates used for annotation were then used to count extended pol II reads falling in the range of TSS 2 30 bp to TSS 1 300 bp and those falling in the remainder of the gene body (TSS 1 301 to TES). Very short transcripts (,630 bp) were excluded, as were cases with very low counts in both regions. Input reads were subtracted and counts were scaled to reads per kilobase. Transcripts sharing identical TSS and TES coordinates were represented a single time in the count statistics. ChIP-seq tracks were smoothed by calculating the density per million mapped reads in 300 bp bins at 50 bp intervals and were visualized using Integrative Genomics Viewer. ChIP-seq density maps were generated using ngsplot 51 (v.2.08). Heatmap of semi-supervised clustering in Fig. 1a of total signal on CDK8 positive regions was carried out as follows: (1) peaks were individually identified for each of the 6 ChIPs using MACS2 at default P value cutoff;
(2) all peaks were combined and merged into non-redundant regions using mergeBed (-d 0); (3) within each unique region, ChIP reads were counted and matched input reads were subtracted after scaling each to million mapped reads; (4) clusters were grouped by ChIPs represented in a given region into 64 categories in the following order: H3K4me1, H3K27ac, pol II, MED1 and BRD4; (5) Technologies) and quantifying by Nanodrop. The difference in copy numbers of specific mRNAs before and after treatment (Fig. 3e) was determined relative to copies of ACTB mRNA per cell. Probes used (Life Technologies): CEBPA (Hs00269972_s1), ETV6 (Hs00231101_m1), IRF1 (Hs00971960_m1), IRF8 (Hs00175238_m1), RREB1 (Hs01002873_m1), CDKN1B (Hs01597588_m1), GFI1 (Hs00382207_m1), JARID2 (Hs01004460_m1), BHLHE40 (Hs01041212_m1), and ACTB (4325788). qRT-PCR for checking siRNA knockdown was performed with iTaq Universal Probes Supermix (Bio-Rad), n 5 3, or by ddPCR.
In vivo studies. Studies were performed at Charles River Laboratories (CRL) and Dana Farber Cancer Institute (DFCI) where indicated and approved by Harvard University and each institution's respective animal care and use committee. For pharmacokinetic studies, serial blood samples from 7-week-old male CD-1 mice (n 5 3 per time point) were collected (no blinding) into K 2 EDTA tubes, centrifuged, transferred into 96-well plates (matrix tubes), stored at 220 uC, and analysed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (in vivo studies performed at CRL). Study size was determined by the need for three blood samples per time point with three blood samples collected per mouse. The MV4;11 xenograft model were performed as previously described 21 (in vivo studies performed at DFCI) Two-million MV4;11-mCLP cells were injected into the tail vein of 7-week-old female non-obese diabetic-severe combined immunodeficient (NOD-SCID) Il2rg 2/2 (NSG) mice (The Jackson Laboratory) and tumour burden was assessed by bioluminescence imaging (BLI) using an IVIS Spectrum system (Caliper Life Sciences). Seven days after injection, leukaemia establishment was documented by BLI and mice were assigned to groups to achieve a similar mean BLI and treated intraperitoneally with vehicle (20% hydroxypropyl-b-cyclodextrin) or CA once daily for 15 days. After 30 days, blood counts were obtained (Hemavet 950 F, Drew Scientific) and spleen, femur and peripheral blood cells were collected and analysed by flow cytometry (LSR Fortessa, BD Biosciences) from three mice per group. The mice and a portion of the spleen were preserved in bouins after body cavities were opened and visceral organs exposed. Samples from all organs were then dissected and placed in nine cassettes per mouse. Tissues were paraffin embedded, sectioned at 6 mm and stained with haematoxylin and eosin. Survival was measured as the time from therapy initiation until moribund state. We selected 11 mice per group to match previous survival analysis in the model 21 (n 5 8) and to have 3 additional mice per group for disease burden comparison. Blinding was only done for histopathology analysis. For the SET-2 xenograft model (in vivo studies performed at CRL), 8-12-week-old female SCID Beige mice (Charles River) were injected subcutaneously in the flank with 10 7 SET-2 cells in 50% matrigel (0.2 ml per mouse). When tumours reached an average size of 80-120 mm 3 , mice were assigned to groups to achieve a similar mean tumour size and treatment commenced without blinding. Tumour volumes were measured using calipers and calculated as (width 2 3 length)/2. Percentage tumour growth inhibition was calculated as mean volumes of (vehicle 2 treatment)/ (vehicle 2 initial) 3 100. We selected 10 mice per group to safeguard against the IACUC requirement to stop dosing a group if .10% mortality occurs. For safety testing (in vivo studies performed at DFCI), 8-week-old female CD-1 mice were treated once daily without blinding for 15 days and weighed daily. Two hours after the last dose, blood counts were obtained and blood chemistry was analysed. Three mice per group were selected as a minimum for comparison. For STAT1-pS727 inhibition, 6-10-week-old female C57BL/6 mice were treated once daily for 2 days (in vivo studies performed at CRL, not blinded). One hour after the second dose, natural killer cells were isolated by dissociation of spleenocytes from isolated spleens, lysis of erythrocytes, and isolation of DX5 1 cells (MiniMACS CD49b, Miltenyi Biotec) and analysed by immunoblot and densitometry (ImageJ, STAT1-pS727 level normalized to b-actin). We selected three mice per group as a minimum for comparison. Statistical analyses were performed using GraphPad Prism 6.0. For P value determinations, two-way or one-way ANOVA was used with Dunnett's multiple comparison testing and P-value adjustment. Dotted purple lines were from the Mouse Phenome Database 22903 (The Jackson Laboratory). No statistical methods were used to predetermine sample size, and experiments were not randomized. Supplementary Fig. 1) . b, CA inhibition in vitro of CDK8 module activity but not CDK12-CCNK or CDK13-CCNK activity up to 10 mM. Equal amounts (silver stain) of GST-CTD were used as the substrate in in vitro kinase assays. The amount of each kinase used was empirically determined to give approximately the same GST-CTD signal under the assay conditions. GST-CTD-P, phosphorylated GST-CTD; ns, no substrate (kinase only). One of four experiments shown. c, Immunoblot showing that CA selectively and dose-dependently inhibits capture of native CDK8 (IC 50 < 10 nM) and CDK19 (IC 50 < 100 nM) from MOLM-14 lysates but does not inhibit capture of CDK9, CDK12, CDK13, ROCK1, ROCK2 or GSG2. One of two experiments shown, full scan in Supplementary Fig. 1 . d, Immunoblots showing CA inhibition of CDK8-dependent IFN-c-stimulated STAT1-S727 phosphorylation in MOLM-14 cells and CA inhibition of TGF-bstimulated Smad2-T220 and Smad3-T179 phosphorylation in HaCaT cells (IC 50 , 100 nM). One of two experiments shown, full scan in Supplementary Fig. 1 . e, In vitro kinase activity profiling (mean for kinase reaction, n 5 2 biological replicates, experiment performed once). f, g, CA dose-dependent inhibition of CDK8-CCNC complex (IC 50 Supplementary Fig. 1 ). c, Immunoblots showing CDK8 and CDK19 levels after 24 h CA treatment in sensitive cell lines MV4;11 and MOLM-14 (one of two experiments shown, full scan in Supplementary Fig. 1 ). d, CD41 and CD61 (vehicle versus CA, P 5 0.04 and 0.005, respectively, two-tailed t-test) on SET-2 cells after 3 days of indicated treatment (mean 6 s.e.m., n 5 3 biological replicates, one of two experiments shown). Phorbol 12-myristate 13-acetate (PMA) was used as positive control. e, DNA content and annexin V staining of indicated cell lines after treatment with CA (mean 6 s.e.m., n 5 3 biological replicates, one of two experiments shown). f, Immunoblots of CA dose-and time-dependent induction of PARP and caspase-3 cleavage for indicated cell lines (one of two experiments shown, full scan in Supplementary Fig. 1 ). 76
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Flag-CDK19 Flag-CDK19 (W105M) Flag-CDK8 (W105M) Numbers in red indicate the percentage of CDK8-occupied genes (peak within 65 kb of the gene). c, d, RNA pol II ChIP-seq metagene profile plots of unchanged genes (black), SE-associated genes (yellow), CA-upregulated genes with vehicle treatment (no CA; red), and CA-upregulated genes with 6 h CA treatment (with CA; blue). e, f, Cumulative distribution plot of RNA pol II travelling ratio (TR) after treatment with CA (25 nM, 6 h) or vehicle across genes $1.2-fold downregulated by CA after 3 h (1.16-fold, P 5 0.31, Kolmogorov-Smirnov test) (e) and across all genes (1.21-fold, P , 2.2 3 10 216 , Kolmogorov-Smirnov test) (f). g, CA does not significantly change the total amount of RNA or mRNA in MOLM-14 or MV4;11 cells (mean 6 s.e.m., n 5 3 biological replicates, experiment performed once) after treatment with CA (25 nM, 3 h). h, Global levels of RNA pol II pS2 or RNA pol II pS5 do not change after treatment with CA by immunoblot analysis. Flavopiridol (FP) was used at 300 nM as a positive control (experiment performed twice, full scan in Supplementary  Fig. 1 ). CD14+  master TFs   ETV6, IRF1, RXRA, SMAD3, BCL11A, FOSL2,  RFX2, CEBPA, RREB1, IRF8, BHLHE40, ZNF217 
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